英威騰(002334.SZ)擬推第二期員工持股計劃 涉及股票數量222萬股
格隆匯6月9日丨英威騰(002334.SZ)披露第二期員工持股計劃(草案),涉及的標的股票數量為222萬股,佔草案公告日公司總股本的0.29%。股票來源於公司2018年5月24日至2018年11月23日專用證券賬户回購的股份。本次員工持股計劃以零價格受讓對等數量的公司回購股票。
本次員工持股計劃參加對象共計62人,其中參加本次員工持股計劃的董事和高級管理人員共計4人,認購總股數為46萬股,佔本次員工持股計劃總份額20.72%;其他員工共計58人,認購總股數為176萬股,佔本次員工持股計劃總份額79.28%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.